Tag: oral

STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a favourable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement. In exploratory efficacy analyses, numerical rapid and sustained improvements in haemodynamics and cardiac structure and function were observed on top of optimised guideline-directed medical therapy (GDMT).

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
—Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

DENVER and MIAMI, June 24, 2026 (GLOBE NEWSWIRE) -- The Western Union Company (“Western Union”) (NYSE: WU) and International Money Express, Inc. (“Intermex”) (NASDAQ: IMXI) today provided an update on the approval process and timeline for Western Union’s pending acquisition of Intermex. To date, money transmission regulators in 51 applicable U.S. states and territories and in all international jurisdictions have provided their approval of or non-objection to the acquisition, and approval or non-objection is currently pending from one U.S. state. Western Union and Intermex remain actively engaged in discussions with regulators, including the New York State Department of Financial Services, to obtain the final regulatory approval. Western Union and Intermex anticipate closing the transaction as soon as reasonably practicable upon receipt of such approval as well as satisfaction of other customary closing conditions.

The move into “America’s Favorite Small Town” strengthens the community bank’s commitment to supporting California’s food, agriculture, and small business economy

BEIJING, June 23, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today officially launched the all-new Li L8, with deliveries to commence within this week. The vehicle is available in Ultra and Livis trims, priced at RMB369,800 and RMB429,800, respectively. For more details on the all-new Li L8, please visit Li Auto’s official website.